Actinium Pharmaceuticals to Present Phase 1 Study of ATNM-400 at ESMO 2026

Actinium Pharmaceuticals will present its Phase 1 study of ATNM-400, a HER3-targeted radiotherapy for metastatic castration-resistant prostate cancer, at the ESMO Congress 2026 in Madrid. This multicenter, open-label trial aims to evaluate the safety, tolerability, and antitumor activity of ATNM-400, which combines a HER3-targeting antibody with Actinium-225. The presentation is expected to enhance visibility into the clinical progress of this investigational therapy.